Holen Sie sich die Stockscreener-App
8.495
0.70%
-0.105
Schlusskurs vom Vortag:
$8.60
Offen:
$8.55
24-Stunden-Volumen:
3,061
Relative Volume:
0.03
Marktkapitalisierung:
$104.43M
Einnahmen:
$57.70M
Nettoeinkommen (Verlust:
$11.98M
KGV:
-14.78
EPS:
-0.5746
Netto-Cashflow:
$-12.24M
1W Leistung:
+0.47%
1M Leistung:
+41.39%
6M Leistung:
-28.17%
1J Leistung:
-30.00%
1-Tages-Spanne:
$8.47
$8.60
1-Wochen-Bereich:
$8.21
$8.7303
52-Wochen-Spanne:
$4.95
$12.94
Lensar Inc Stock (LNSR) Company Profile
Firmenname
Lensar Inc
Sektor
Branche
Telefon
888-536-7271
Adresse
2800 DISCOVERY DRIVE, ORLANDO
Compare LNSR vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LNSR
Lensar Inc
|
8.50 | 105.66M | 57.70M | 11.98M | -12.24M | -0.5746 |
ABT
Abbott Laboratories
|
106.22 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.67 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
271.96 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.77 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.52 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lensar Inc Stock (LNSR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Hochstufung | Lake Street | Hold → Buy |
| 2026-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-02-24 | Eingeleitet | SVB Leerink | Outperform |
Lensar Inc Aktie (LNSR) Neueste Nachrichten
(LNSR) Risk Channels and Responsive Allocation - Stock Traders Daily
LNSR stock holds at $8.29 as Lensar fundamentals and laser platform shape the outlook - AD HOC NEWS
LENSAR Inc. (LNSR) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Lensar Inc Earnings Call Highlights Growth Momentum - The Globe and Mail
BTIG Maintains LENSAR(LNSR.US) With Buy Rating, Raises Target Price to $10 - Moomoo
LENSAR (LNSR) Q2 2026 Earnings Call Transcript - AOL.com
LENSAR (NASDAQ:LNSR) Price Target Raised to $10.00 - MarketBeat
LNSR Maintains Buy Rating by BTIG -- Price Target Raised to $10. - GuruFocus
DCF Advisers LLC Purchases New Position in LENSAR, Inc. $LNSR - MarketBeat
LENSAR (LNSR) Session: Ends Up by 1.71% at $8.33 in Latest Trading; Price Context: $7.91 and $8.75 Define the Nearby Reference Levels for the Current SessionRSI Overbought Alerts - vinanet.vn
LENSAR (LNSR) Trading Summary: Gains 1.24% to Reach $8.19 in Latest Trading; Range Context: the Current Price Sits Inside the Supplied Technical Range at the CloseCall Resistance - vinanet.vn
LNSR Q2 2026 Earnings: EPS Swings to Profit, Delivering 159.42% SurpriseEarnings Momentum Score - vinanet.vn
LNSR Looks 65.7% Overvalued on GF Value™ - GuruFocus
Trading the Move, Not the Narrative: (LNSR) Edition - Stock Traders Daily
LNSR Q2 2026 Earnings: Strong EPS Beat vs. Estimates Despite Soft Share ReactionNext Quarter Guidance - vinanet.vn
LENSAR Q2 recurring revenue hits USD 13.7M - Medical Buyer
LENSAR Inc. (LNSR) Holds Above Support at $8.20 After Modest PullbackRounding Bottom - vinanet.vn
LENSAR (NASDAQ:LNSR) Upgraded at Wall Street Zen - MarketBeat
Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback - Stocktwits
Curis: Q2 Earnings Snapshot - AOL.com
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $13 - Moomoo
LENSAR-Ergebniskonferenz Q2 2026: Umsatz steigt um 18 % dank steigender wiederkehrender Umsätze - TradingKey
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
LENSAR earnings beat by $0.31, revenue topped estimates - Investing.com Canada
Q2 2026 LENSAR Inc Earnings Call Transcript - GuruFocus
Lensar Returns to Profit in Q2 on Strong Demand for ALLY Cataract System - VisionMonday.com
LENSAR Inc (LNSR) (Q2 2026) Earnings Call Highlights: Record Rev - GuruFocus
LENSAR Inc (LNSR) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge - Yahoo Finance
LENSAR (LNSR) swings to profit on $39.9M H1 net income and $10M merger fee - Stock Titan
LNSR Looks 44.6% Overvalued on GF Value™ - GuruFocus
LNSR Q2 2026 Earnings: EPS Beats Estimates by Wide Margin, Shares Surge 29.41%Core Business Growth - Vinanet
LENSAR (NASDAQ:LNSR) Posts Quarterly Earnings Results, Beats Expectations By $0.26 EPS - MarketBeat
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Raises Target Price to $13 - Moomoo
LENSAR Q2 Earnings Call Highlights - MarketBeat
LENSAR, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LNSR Maintained by BTIG -- Price Target Raised to $9.00 - GuruFocus
BTIG Research Forecasts Strong Price Appreciation for LENSAR (NASDAQ:LNSR) Stock - MarketBeat
Earnings call transcript: LENSAR beats on Q2 2026 profit, shares jump premarket - Investing.com Canada
LENSAR Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lensar Q2 EPS $0.10 beats estimate; sales up 18% to $16.5M - scanx.trade
Why is LENSAR stock surging today? By Investing.com - Investing.com South Africa
Why is LENSAR stock surging today? - Investing.com India
Is LENSAR Inc (LNSR) Overvalued After Q2 Earnings? EPS: $0.13, R - GuruFocus
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Form 8K LENSAR Inc For: 13 August By Investing.com - Investing.com Nigeria
LENSAR Q2 Revenue Rises 18% as Net Income Reaches $3.5 Million - Quiver Quantitative
LENSAR Reports Q2 2026: Revenue $16.5M, Recurring Revenue $13.7M, Net Income $3.5M - TradingView
LENSAR (LNSR) swings to Q2 2026 profit as revenue and ALLY usage climb - Stock Titan
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update - marketscreener.com
LENSAR Places 10 Robotic Cataract Lasers; 13 Await Installation - Stock Titan
Earnings To Watch: LENSAR Inc (LNSR) Q2 2026 -- GF Value Sees 13% Upside - Yahoo Finance
Finanzdaten der Lensar Inc-Aktie (LNSR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lensar Inc-Aktie (LNSR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STAAB THOMAS R II | Chief Financial Officer |
Mar 19 '26 |
Option Exercise |
2.65 |
5,500 |
14,575 |
175,959 |
0.81%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):